MG
CPRX

Mather Group’s Catalyst Pharmaceutical CPRX Stock Holding History

Mather Group’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.27K Buy
+132
New +$3.15K ﹤0.01% 1637
2025
Q4 		– Sell
-132
Closed -$2.6K – 851
2025
Q3 		$2.6K Buy
+132
New +$2.71K ﹤0.01% 1501
2025
Q2 		– Sell
-132
Closed -$3.2K – 841
2025
Q1 		$3.2K Hold
132
– – ﹤0.01% 1487
2024
Q4 		$2.75K Hold
132
– – ﹤0.01% 1485
2024
Q3 		$2.62K Sell
132
-333
-72% -$6.17K ﹤0.01% 1426
2024
Q2 		$7.41K Buy
+465
New +$7.24K ﹤0.01% 1525

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Mather Group's CPRX Position: Q1 2026 in Review

Mather Group opened a new position in Catalyst Pharmaceutical (CPRX) in Q1 2026: 132 shares worth $3.27K. The stake represents ﹤0.01% of the portfolio and ranks #1637 among its holdings. This is a return to the name: Mather Group previously reported a position in CPRX as recently as Q3 2025.

Mather Group first reported a position in CPRX in Q2 2024 and has held it in 6 quarters since. The position peaked at $7.41K in Q2 2024. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Mather Group held 132 shares of Catalyst Pharmaceutical worth $3.27K as of Q1 2026.
  • Catalyst Pharmaceutical was a new Mather Group position in Q1 2026.
  • Catalyst Pharmaceutical made up ﹤0.01% of Mather Group's portfolio in Q1 2026, its #1637 holding.
  • Mather Group first reported a position in Catalyst Pharmaceutical in Q2 2024 and has held it in 6 quarters since.
  • Mather Group's Catalyst Pharmaceutical position peaked at $7.41K in Q2 2024.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Mather Group's 13F filing for Q1 2026, filed 13 Apr 2026.